Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Chrs save search
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 5.0%
H: 1.59%
C: -3.17%
il-27 symposium asco positive
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - biospace.com/
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Published: 2023-02-15 (Crawled : 15:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.13%
H: 0.63%
C: -1.13%
piter-02 treatment trial positive
Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
Published: 2022-10-12 (Crawled : 13:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -1.15%
H: 1.63%
C: -0.93%
hoice-01 treatment lung trial positive publication
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -1.15%
H: 1.63%
C: -0.93%
hoice-01 trial positive results publication
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 pos presentation positive results positive bioscience results
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published: 2022-03-04 (Crawled : 19:00) - biospace.com/
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
pos cel positive results positive bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published: 2022-03-04 (Crawled : 19:00) - biospace.com/
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
pos cel positive results positive bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
Published: 2021-10-05 (Crawled : 13:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.61%
H: 1.09%
C: 0.11%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.25%
H: 4.54%
C: 2.02%
positive results positive results trial
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-17 (Crawled : 01:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06
Published: 2021-09-16 (Crawled : 23:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.44%
H: 0.47%
C: -0.15%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.7%
H: 2.3%
C: 2.23%
positive results
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-19 (Crawled : 02:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.92%
H: 2.37%
C: 1.48%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.27%
H: 8.73%
C: 1.47%
treatment lung cancer positive therapy results cancer phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.